麻豆传媒

How GLP-1 drugs are reshaping medicine

But how to achieve equitable use remains "complicated," says expert

In the third year, 88% of patients could go 12 weeks or longer with 8-mg dose

Ophthalmologists hope expanded use will lead to more evaluations in primary clinics

Data too uncertain to support sotagliflozin in subset with chronic kidney disease, advisors say

SGLT1/SGLT2 inhibitor has another shot in T1D, but now in more narrow patient population

Findings leave researcher "concerned"

Problem linked to 170 reports of hyperglycemia and 11 ketoacidosis cases

Health news and commentary gathered by 麻豆传媒 staff

The three companies process about 80% of prescriptions in the U.S.

But higher severe hypoglycemia risk with efsitora in type 1 diabetes likely precludes its use

Clinical disease incidence jumped after infection

Adolescence is a critical period in T1D, associated with hyperfiltration and high HbA1c levels

INHALE 3 provides insights into dosing and who might actually do worse than with a pump